Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 6/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3630509 | 0.88 | LMNA (0.45) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6906558 | 0.88 | LMNA (0.45) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL10903345 | 0.86 | CDA (0.42) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL31436719 | 0.86 | CDA (0.42) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL27845966 | 0.84 | CDA (0.41) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17440122 | 0.84 | CDA (0.41) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL29845228 | 0.84 | CDA (0.41) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL22978939 | 0.84 | CDA (0.41) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4751008 | 0.84 | LMNA (0.42) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL10903331 | 0.84 | LMNA (0.42) | CDASLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123207-A1 | 5'-О-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE AND USE THEREOF | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | 2024-06-13 | — | — | WO | claimed |
| EP-4149252-A2 | ENGINEERED GENE-EDITING PROTEINS | Factor Bioscience Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| CN-113784721-B | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-116554249-B | Antiviral compounds and uses thereof | 北京恩泰伟医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119139338-A | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119125384-A | Method for determining concentration of Mo Nuola-pyrrosid and/or active metabolite beta-d-N4-hydroxycytosine in human body fluid based on liquid chromatography-mass spectrometry after chemical derivatization of benzoyl chloride | 中国人民解放军海军军医大学第一附属医院 | 2024-12-13 | — | — | CN | disclosed |
| CN-118948877-A | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118922430-A | Preparation method of monabivalir and intermediate thereof | 上海科胜药物研发药物有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4430055-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| EP-4430055-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| CN-118591377-A | Antiviral prodrugs, intermediate and long acting formulations and methods | 加利福尼亚大学董事会 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023083295-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| EP-4149252-A2 | ENGINEERED GENE-EDITING PROTEINS | Factor Bioscience Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115768474-A | Methods for treating COVID-19 related disorders | 里格尔药品股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115666587-A | N4-hydroxycytidine and derivatives and related antiviral uses thereof | 埃默里大学 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022262845-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022262845-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| CN-108463103-B | Targeted mutagenesis of tobacco berberine bridge enzyme-like nucleic acids | 北卡罗来纳州立大学 | 2022-08-26 | — | — | CN | disclosed |
| CN-101862345-B | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation | GILEAD SCIENCES INC | 2014-06-04 | — | — | CN | disclosed |
| CN-101862345-A | The modified nucleosides that is used for the treatment of viral infection and abnormal cell proliferation | PHARMASSET LTD | 2010-10-20 | — | — | CN | disclosed |